Abel Hall LLC
TVTX icon

Abel Hall LLC’s Travere Therapeutics TVTX Stock Holding History

Abel Hall LLC’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$367K Buy
6,237
+42
+0.7% +$2.56K 0.07% 344
2026
Q2 		$352K Buy
+6,195
New +$275K 0.06% 395

Other funds holding TVTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Insight Wealth Strategies
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
OpenArc Corporate Advisory
OpenArc Corporate Advisory Atlanta, Georgia $8.86B AUM 19.31% 1-Year Est. Return
Burney Company
Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Wealthcare Advisory Partners
Wealthcare Advisory Partners West Chester, Pennsylvania $5.9B AUM 14.62% 1-Year Est. Return

Abel Hall LLC's TVTX Position: Q3 2026 in Review

Abel Hall LLC increased its Travere Therapeutics (TVTX) stake by 0.68% in Q3 2026, buying an estimated $2.56K and bringing the position to 6,237 shares worth $367K. The position accounts for 0.07% of the portfolio, ranked #344.

Abel Hall LLC first reported a position in TVTX in Q2 2026 and has held it in 2 quarters since. 33 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • Abel Hall LLC held 6,237 shares of Travere Therapeutics worth $367K as of Q3 2026.
  • Abel Hall LLC bought 42 Travere Therapeutics shares in Q3 2026, an estimated $2.56K.
  • Travere Therapeutics made up 0.07% of Abel Hall LLC's portfolio in Q3 2026, its #344 holding.
  • Abel Hall LLC first reported a position in Travere Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 33 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.